SCHEMBL13250064

SCHEMBL13250064

Cc1nc2c(c(=O)n1C(c1ccc(Cl)cc1)c1ccc(Cl)cc1)CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
MKNK1 Q9BUB5 3/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ESR2 Q92731 1/20 0.40
CNR1 P21554 3/20 0.39
NR1H2 P55055 1/20 0.39
F12 P00748 1/20 0.39
MAPT P10636 2/20 0.38
P2RX3 P56373 1/20 0.38
MTOR P42345 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP3A5 P20815 1/20 0.37
STS P08842 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13249998 0.96 PARP1 (0.44) PARP1TNKS2PARP2MKNK1MEN1
SCHEMBL13250004 0.90 PARP1 (0.44) PARP1TNKS2PARP2MKNK1ESR2
SCHEMBL13249769 0.90 PARP1 (0.48) PARP1TNKS2PARP2ESR2NR1H2
SCHEMBL13328818 0.89 PRLHR (0.42) CNR1MAPTPRLHR
SCHEMBL13250092 0.87 PARP1 (0.44) PARP1TNKS2PARP2MKNK1MEN1
SCHEMBL13249990 0.86 PARP1 (0.43) PARP1TNKS2PARP2F12MAPT
SCHEMBL13250459 0.85 PARP1 (0.42) PARP1TNKS2PARP2F12P2RX3
SCHEMBL13250018 0.83 PARP1 (0.46) PARP1TNKS2PARP2MKNK1NR1H2
SCHEMBL13250080 0.83 PRLHR (0.38) PRLHR
SCHEMBL13250063 0.83 PARP1 (0.40) PARP1TNKS2PARP2MAPTP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 US disclosed
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GCGR, GPR65 PARP1 995/4885TNKS2 2045/4885PARP2 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.